Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mustang Bio's CAR T Therapy Achieves Complete Response | Contract Pharma

What are you searching for?

Sign in
Breaking News

Mustang Bio’s CAR T Therapy Achieves Complete Response

Investigators found infusions of MB-102 are safe and well tolerated

By: Betsy Louda

, Contract Pharma

Mustang Bio has announced City of Hope’s report that their MB-102 (CD123 CAR) CAR T therapy is safe and has achieved the first-ever complete response from a CAR T therapy in blastic plasmacytoid dendritic cell neoplasm (BPDCN), as well as a CR in acute myeloid leukemia (AML), in an ongoing Phase 1 clinical trial. 

 

Manuel Litchman, M.D., president and chief executive officer of Mustang, said, “According to investigators at City of Hope, these data demonstrate MB-102’s potential to be a safe, well tolerated and effective CAR T therapy that can achieve complete disease response. In addition, MB-102’s promising anti-leukemic activity in both AML and BPDCN supports further evaluation in clinical trials in transplant eligible and ineligible patients. 

 

This single center, first-in-human Phase 1 dose-escalation clinical trial is evaluating the safety and activity of escalating doses of MB-102 in patients with relapsed or refractory AML (cohort 1) and BPDCN (cohort 2). Patients receive a single dose of MB-102 with an option for a second infusion if they continue to meet safety and eligibility criteria and still have CD123+ disease. To date, 14 patients have been enrolled and seven have been treated in this first in-human trial for AML and BPDCN patients using a CD123 CAR T therapy.


In the AML cohort, two patients were treated at dose level 1. Trial investigators reported that one achieved a morphologic leukemic-free state at day 28 post-infusion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics